Introduction
On August 13, 2025, President Trump signed a sweeping Executive Order titled “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve.” The order addresses a long-standing vulnerability in the U.S. healthcare system, the nation’s heavy reliance on foreign suppliers for the active pharmaceutical ingredients (APIs) that make up the backbone of essential medicines.
With this action, the administration is directing the Assistant Secretary for Preparedness and Response (ASPR) at the Department of Health and Human Services (HHS) to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). The goal is to maintain a six-month supply of APIs for roughly 26 critical drugs deemed essential to national health and security.
Why This Matters: Background & Context
The United States currently produces only about 10% of the APIs used in prescription drugs domestically. The rest are largely imported, with China and India holding a dominant position in the global API market. This dependency leaves the U.S. vulnerable to disruptions, whether from geopolitical tensions, trade restrictions, or pandemic-driven shortages.
The COVID-19 pandemic revealed the risks of this dependency as hospitals faced shortages of antibiotics, antivirals, and sedatives. While federal agencies and lawmakers have since called for reshoring pharmaceutical production, progress has been slow, and market forces alone have not solved the problem.
Inside the Executive Order: Key Provisions
The EO lays out several decisive measures:
- Expansion of the SAPIR – this order aims to refill the existing SAPIR stockpile and open a 2nd repository to further enhance pharmaceutical supply chain resilience.
- Critical Drugs List – ASPR will identify approximately 26 critical drugs for inclusion, focusing on those vital to public health, emergency response, and national defense.
- Six-Month Stockpile Goal – Sufficient API used to produce 26 critical drugs will be stored to meet national demand for half a year. This Executive Order prioritizes domestically-manufactured APIs to protect the supply chain from potential disruptions.
- Essential Medicines List – ASPR plans to update the list of 86 essential medicines and propose a plan to obtain and store a 6-month API supply.
Strategic Importance
This shift from reactive crisis management to proactive readiness marks a significant change in federal pharmaceutical policy. By stockpiling APIs instead of finished products, the U.S. gains manufacturing flexibility, reduces costs, and mitigates the risk of expiring medicines.
The move also sends a clear market signal that domestic API production will be a priority. For pharmaceutical manufacturers, this could mean new opportunities for federal contracts, incentives for facility expansion, and long-term policy support for reshoring efforts.
From a national security perspective, the reserve reduces America’s exposure to supply disruptions caused by overreliance on foreign nations, trade disputes, or natural disasters affecting overseas production facilities.
Potential Impacts Across Sectors
Public Health Preparedness
A well-maintained API reserve ensures that hospitals, pharmacies, and emergency responders can access life-saving medications during crises without relying on unpredictable foreign suppliers.
Industrial Policy & Manufacturing
Incentivizing domestic API production could drive investment in advanced manufacturing technologies, such as continuous flow synthesis, making U.S. facilities more competitive on a global scale.
Policy & Legislative Dynamics
While Congress has debated similar measures, the EO bypasses lengthy legislative processes and provides immediate policy direction. Legislative action may still be needed for long-term funding and statutory authority to expand the program.
Broader Policy Trajectory
The Executive Order aligns with earlier Trump administration initiatives aimed at reducing regulatory barriers for domestic pharmaceutical production and cutting dependence on foreign supply chains. It also reflects bipartisan recognition spanning both the Biden and Trump administrations that pharmaceutical supply resilience is both a public health and national security imperative.
Conclusion & What to Watch Next
The growth in the Strategic Active Pharmaceutical Ingredients Reserve is a milestone in U.S. supply chain policy, but its success will depend on implementation. Key questions remain:
- How quickly can ASPR identify and procure APIs for the targeted drug list?
- Will domestic manufacturing capacity be sufficient to meet stockpile needs?
- Could the program expand beyond the initial 26 drugs to include a broader range of critical drugs?
If expanded effectively, SAPIR could protect Americans from drug shortages and serve as a model for other sectors facing similar supply chain vulnerabilities. For pharmaceutical manufacturers, healthcare providers, and policymakers, this is a development worth watching closely.
If your company has considered applying for federal funding, your federal funding journey starts here. EverGlade Consulting is a national firm that helps organizations win and manage federal awards. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ARPA-H, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
